Merck has announced that it will be presenting new drug data at the forthcoming American Society of Clinical Oncology (ASCO) 2018 Gastrointestinal Cancers Symposium.
The company will attend the conference in San Francisco from January 19th to 21st, where it will present a total of three abstracts on M7824, an investigational early-phase PD-L1/TGF-beta bifunctional immuno-oncology asset.
“Merck will be presenting new data on immunotherapy innovations at this year's ASCO Gastrointestinal Cancers Symposium.“
According to the preliminary evidence, combining anti-PD-L1 and TGF-beta trap mechanisms in a single molecule has the potential to generate antitumour activity in some heavily pretreated patient populations who are in significant need of new therapies.
The new clinical data will demonstrate the benefits M7824 provided in a study involving heavily pretreated Asian patients with recurrent or refractory unresectable advanced gastric and gastroesophageal adenocarcinoma.
Dr Luciano Rossetti, executive vice-president and global head of research and development at Merck's biopharmaceuticals division, said: "The data adds to our deepening knowledge of the therapeutic potential of this bi-functional immunotherapy, allowing us to further sharpen our focus on indications where we have the highest potential to make a real difference for patients."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical